This section provides answers to questions asked during the Division of AIDS (DAIDS) Remote Monitoring Discussion session on April, 20 2020. Additional information from the session, including a full recording and slides, are available on the DAIDS Resources and Announcements page under DAIDS Presentations.

Please email if you have additional questions about DAIDS remote monitoring.

Document Transmission

The site should ensure there are no participant identifiers on any of the documents sent.

No, they do not need to be certified copies, as they are not source documents.

Our site's research compliance department prefers that we virtually share documents in this manner for remote monitoring visits. Yes, this is acceptable and a great suggestion. Please be aware that the call may take longer.

We are looking into some options for file sharing; however, due to security concerns at this time we only have Microsoft Teams that could be a possibility for that. Kindly check with your monitor

Lockdown Constraints and Limitations

Check with your IRB – they may be meeting virtually or there may be exceptions for the use of expedited reviews temporarily. Document all efforts. Also check with your PO to determine next steps.

If there are no staff at the site who can provide the documents, the monitor will continue with the remote visit using the documents available in Protocol Registration and will indicate that in the report. The monitor will then follow-up when restrictions are lifted, and the onsite visit can occur.

The monitor can review the log without the signatures and make a note in the report to follow-up when onsite visit resumes.

Monitoring Scope

If the site cannot participate in the remote review process, the site should provide a reason which will be documented. 

The monitoring process will continue with the remote review of documents available in Protocol Registration and CRF review in the EDC system (Ex. Medidata, OpenClinica).  The visit report will be released within the usual timeframe and will include the reason the site was unable to participate in the remote visit process.

No, WESTAT is a separate entity. We recommend that you contact WESTAT for guidance on their monitoring approach during COVID-19 pandemic.

Yes, monitors will be reviewing essential documents in the N-CRMS Protocol Registration system; therefore, it is important to ensure those files are current.

No, we do not intend to change any PRO process and will not require that you send Financial Disclosures to PRO.

Yes, we will continue with that practice by reviewing the eCRF in the EDC of any PID.

Monitors would be looking for ICF versions and dates signed, both initial and subsequent consents.  The purpose is for logic checks against CRFs. Not all sites maintain ICF logs, but if your site does, it would greatly assist with the remote data reviews.

We expect that the approach being taken by site personnel and monitors will be similar to the ones taken for domestic remote monitoring.  We assume that the challenges regarding availability of site staff, guidance by local regulatory entities due to COVID 19 will be similar.

Monitoring Process

No access will be required at this time; no source documents will be reviewed.

An example would be if the participant’s year of birth is noted to be 1995 on an entry eCRF, but a lab CRF indicates the participant’s age as 45.

If the time is not indicated, we would only be able to use the dates on eCRFs and Lab results.

The monitoring activity should be indicated as the date range of the first review call and the debriefing call with the CRS Leader.

Example: The initial call with study coordinator is 4/21 and debriefing call with the CRS Leader is 4/22. Visit would be documented as 4/21-22/2020.  The two calls may also happen on the same date.

Yes, the site and the program officer will receive the report at the same time.  However, all findings will be reported as “Other” observations until the monitor has completed an onsite verification of the data.

The calls can range from 30 minutes to a maximum of 2 hours. This is dependent upon how complete the pre-visit preparation is and how many findings there are to cover.

Please provide the DAIDS Memo​ dated on April 6th, 2020 to your IRB.


No Accountability logs or scripts should be requested or sent; only temperature logs will be requested.


No, the monitor will request a separate call with the Pharmacist of Record.

Document the situation and discuss with your PO.

The situation should be indicated within the Site Monitoring Report which should be sufficient. If it is not mentioned in the report, please discuss with your PO.

Long-Term Impacts

We don’t anticipate that remote monitoring SMRs will impact performance evaluation.

At this time, it is unclear how long the restrictions will be in place.